Diagnoses Disease, Vasculitis
Conditions
Keywords
Vasculitis, LV-GCA, Giant cell arteritis, FDG-PET, Imaging, CXCR4
Brief summary
Giant cell arteritis (GCA) is the most common vasculitis in the elderly. Accurate diagnosis is of utmost importance in order to then initiate the necessary immunosuppressive therapy. For large-vessel GCA (LV-GCA) involving the aorta and its branches, FDG-PET/CT is the standard in imaging for diagnosis and is recommended by the guidelines. However, this only indirectly visualizes inflammation through vessel wall uptake of glucose. A new PET tracer, 68Ga-pentixafor, is used to visualize the chemokine receptor CXCR4. This receptor is expressed by cells of the immune system. In the context of inflammatory processes, upregulation of CXCL12, the ligand of CXCR4, occurs in affected tissues. The chemotactic effect of this ligand leads to the immigration of CXCR4-positive inflammatory cells into the inflamed area, which can be visualized by PET using the CXCR4-specific tracer 68Ga-Pentixafor. The value of CXCR4-PET should therefore be tested in the context of LV-GCA. This study tests the benefit of CXCR4 in therapy-naïve patients with suspected LV-GCA. For this purpose, patients will receive a FDG-PET and a CXCR4-PET for direct comparison. This is an imaging-only study. Therapy will not be affected by the study. The study is single-arm and not blinded.
Interventions
DIAGNOSTIC_TESTCXCR4-PET
New imaging modality using CXCR4 for imaging in GCA
Sponsors
Matthias Fröhlich
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* New diagnosis of GCA within 5 days of diagnosis or initiation or intensification of therapy. * Evidence of inflammatory activity based on clinical parameters, elevated serologic markers of inflammation (CRP \> 1.0 mg/dl), or a positive imaging finding on vasculitis MRI, CCDS, or FDG-PET/CT * Ability of the patient to provide information * Exclusion of contraindications for the performance of a PET/CT examination (see below)
Exclusion criteria
* Contraindications for the performance of a PET CT examination * Pregnancy * Allergies * Lack of capacity of the patient to give informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum measurable tracer activity on 68Ga-Pentixafor PET/CT in the area of blood vessels in active GCA | 2 years | detection of maximum measurable tracer activity on 68Ga-Pentixafor PET/CT in the area of blood vessels after a maximum of 5 days after diagnosis or when acute inflammatory activity of GCA is detected in terms of recurrence. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation with clinical parameters | 2 years | Correlation of the measured tracer activity with clinically and laboratory-chemically available parameters that are collected in clinical routine. These include CRP, peripheral blood leukocyte count, calprotectin, serum amyloid A, haptoglobin and Lactate dehydrogenase and their respective progression. |
| Correlation with blood leukocyte count | 2 years | Correlation of tracer uptake on imaging with CXCR4-positive peripheral blood leukocyte count. |
| Comparison to other imaging modalities | 2 years | Comparison with imaging findings from vasculitis MRI imaging implemented in standard clinical practice, duplex sonography (CCDS), and, if performed as part of routine clinical practice, FDG PET/CT data. |
Countries
Germany
Outcome results
None listed